• We are a fully integrated vaccine company with two travel vaccines on the market.

  • Dedicated to innovation in vaccine research and development.

  • Valneva’s R&D focuses on vaccines addressing high unmet medical needs.

  • Valneva covers the full value chain from research to market.

Welcome to Valneva
A fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines.


Download 2017 Valneva Annual Business Report

November 8, 2018
Valneva Reports Nine Month Results for 2018, Confirms Guidance, Strengthens Balance Sheet with €50m Financing

Read more

— Stock information


— October 25, 2018
Valneva Receives Positive Feedback from EMA on further Development for Lyme Disease Vaccine VLA15

Read more
— Financial Calendar

November 8, 2018
Nine Months Results 2018

The webcast from the event can be accessed here.

See all dates


News in German


Images, presentations and videos


learn more
play video Company Video

– Upcoming conferences

November 13-14
Stifel 2018 Healthcare Conference, New York

November 14-15
Jefferies 2018 Healthcare Conference, London

January 7-10, 2019
Investor meetings during Annual JP Morgan healthcare conference, San Francisco

April 15-17, 2019
World Vaccine Congress, Washington D.C.
Please update your browser...